AG真人官方

Compass, Inc. filed a Form D reporting completion of a $501,897 private placement of Class A common stock under Rule 506(b). The shares were issued on 16 Jul 2025 to a single investor in satisfaction of a hold-back obligation from a prior acquisition; therefore the transaction is tied to a business-combination settlement rather than a new cash raise.

The New York-based Delaware corporation is classified as operating in the Residential AG真人官方 Estate industry and discloses annual revenue of over $100 million. Minimum outside investment was $10,000; no non-accredited investors participated. No sales commissions or finder鈥檚 fees were paid, and the issuer does not expect the offering to continue beyond one year.

Given the company鈥檚 revenue scale, the 0.5 million-dollar issuance appears immaterial and enables Compass to conserve cash while meeting acquisition-related obligations with negligible dilution.

YSX Tech. Co., Ltd, a Cayman-incorporated holding company that operates in mainland China through VIE structures, filed its FY 2025 Form 20-F for the year ended 31 Mar 2025. The company鈥檚 Class A ordinary shares trade on Nasdaq under ticker YSXT; 22,260,175 Class A and 1,177,325 Class B shares were outstanding at period-end. YSXT is a non-accelerated filer and an emerging-growth company preparing accounts under U.S. GAAP.

The filing contains no income-statement or cash-flow data but devotes extensive disclosure to PRC regulatory risks: potential government intervention, cybersecurity review, data-export controls, SAFE registration, capital controls, and uncertainties under the CSRC overseas-listing rules. Management details exposure to the HFCAA鈥攚hile the current auditor is PCAOB-inspected, future access could change鈥攑lus constraints on dividend remittance from China or Hong Kong. Other highlighted risks include social-insurance shortfalls (鈮圲S$0.11 m estimated), rising labor costs, and geopolitical trade tensions. The company confirms it currently does not qualify as a Critical Information Infrastructure Operator, has received no CAC review notice, and believes no PRC permissions are presently denied, but warns that requirements could emerge.

CAMP4 Therapeutics (CAMP) filed a Form 4 disclosing the award of 9,000 non-qualified stock options to director Ravi I. Thadhani on 25 Jun 2025. The options carry an exercise price of $1.56 and expire on 24 Jun 2035. They vest in full on the earlier of one year from grant or the company鈥檚 next annual shareholder meeting, contingent on continued board service. No shares were bought or sold, and Mr. Thadhani鈥檚 total beneficial ownership now reflects these newly granted options. The filing represents routine director compensation and does not involve open-market transactions or changes to outstanding share count.